VIDEO: 'Very respectable' outcomes with datopotamab deruxtecan in lung cancer subsets
Click Here to Manage Email Alerts
In this video, Edward B. Garon, MD, MS, discusses findings from the TROPION-PanTumor01 study presented at ESMO 2021.
The phase I study assessed datopotamab deruxtecan among patients with previously treated advanced or metastatic non-small cell lung cancer
Garon, associate clinical professor of medicine and hematology-oncology at the University of California Los Angeles David Geffen School of Medicine, noted that while overall results from the study were previously presented at World Lung, the findings presented at ESMO focused on patients with various genomic alterations of lung cancer.
Of the 210 patients involved in the study, a total of 34 with actionable genomic alterations — including 29 patients with EGFR mutations — were assessed in these results.
Garon said that “one of the key takeaways was very respectable outcome data that we have from this study in the patients with actionable genomic alterations, with somewhere in the 35% range of the patients having a response to therapy [and] with the duration of response also being good.”
Collapse
Garon EB, et al. LBA49. Presented at: ESMO 2021 (virtual meeting); Sept. 16-22, 2021.
Read more about
Click Here to Manage Email Alerts